ADMA Biologics (NASDAQ:ADMA) Shares Down 3.4% – What’s Next?

ADMA Biologics, Inc. (NASDAQ:ADMA)’s share price fell 3.4% during trading on Friday . The company traded as low as $21.01 and last traded at $21.08. 348,220 shares were traded during trading, a decline of 90% from the average session volume of 3,606,443 shares. The stock had previously closed at $21.83.

Analysts Set New Price Targets

ADMA has been the topic of several research analyst reports. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research note on Friday, November 8th. Cantor Fitzgerald reiterated an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a research report on Friday, September 20th. Finally, Raymond James boosted their target price on shares of ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research note on Friday, November 8th.

ADMA Biologics Trading Down 8.6 %

The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. The firm’s 50-day moving average is $19.08 and its 200 day moving average is $15.23. The firm has a market capitalization of $4.72 billion, a price-to-earnings ratio of 72.86 and a beta of 0.64.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, topping the consensus estimate of $0.13 by $0.02. The company had revenue of $119.84 million for the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the firm posted $0.01 earnings per share. On average, equities analysts predict that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Insider Buying and Selling

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction on Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares of the company’s stock, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, CFO Brad L. Tade sold 15,000 shares of ADMA Biologics stock in a transaction dated Friday, November 22nd. The stock was sold at an average price of $21.15, for a total value of $317,250.00. Following the completion of the transaction, the chief financial officer now directly owns 199,433 shares of the company’s stock, valued at approximately $4,218,007.95. This trade represents a 7.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 3.70% of the stock is owned by insiders.

Institutional Trading of ADMA Biologics

Several large investors have recently modified their holdings of the stock. Hollencrest Capital Management bought a new position in ADMA Biologics during the third quarter worth $30,000. Larson Financial Group LLC bought a new stake in shares of ADMA Biologics during the third quarter worth about $31,000. National Bank of Canada FI acquired a new stake in shares of ADMA Biologics in the 3rd quarter worth about $35,000. Quest Partners LLC bought a new position in ADMA Biologics in the 2nd quarter valued at about $29,000. Finally, Harvest Fund Management Co. Ltd acquired a new position in ADMA Biologics during the 3rd quarter valued at about $62,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.